Binding molecules for the treatment of cancer

A binding molecule comprising:

• (a) at least one antigen binding site that binds specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), wherein the at least one antigen binding site that binds specifically to TRAILR2 comprises heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:73 (CDR1), SEQ ID NO:74 (CDR2) and SEQ ID NO:75 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO:77 (CDR1), SEQ ID NO:78 (CDR2) and SEQ ID NO:79 (CDR3);
• and
• (b) at least one antigen binding site that binds specifically to cadherin-3 (CDH3), wherein said at least one antigen binding site that binds specifically to CDH3 is selected from the group consisting of:
• i. an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:3 (CDR1), SEQ ID NO:4 (CDR2) and SEQ ID NO:5 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8 (CDR2) and SEQ ID NO:9 (CDR3);
• ii. an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO:17 (CDR1), SEQ ID NO:18 (CDR2) and SEQ ID NO:19 (CDR3);
• iii. an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:23 (CDR1), SEQ ID NO:24 (CDR2) and SEQ ID NO:25 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO:27 (CDR1), SEQ ID NO:28 (CDR2) and SEQ ID NO:29 (CDR3);
• and
• iv. an antigen binding site comprising heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:33 (CDR1), SEQ ID NO:34 (CDR2) and SEQ ID NO:35 (CDR3) and light chain CDRs comprising the amino acid sequences of SEQ ID NO:37 (CDR1), SEQ ID NO:38 (CDR2) and SEQ ID NO:39 (CDR3).